Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Curis, Inc. (NASDAQ: CRIS) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of innovative therapeutics for the treatment of cancer. The company operates within the biopharmaceutical and oncology drug development industries, with a strategic emphasis on precision medicines that target key cancer-driving pathways. Curis’ activities are primarily centered on developing small-molecule and antibody-based therapies for hematologic malignancies and solid tumors.
The company’s core revenue drivers historically have consisted of collaboration payments, licensing revenue, and research funding from strategic partners, rather than product sales, as Curis does not currently have an FDA-approved commercial product. Curis is positioned as a translational oncology company with deep expertise in targeted therapeutics, particularly in pathways related to cell signaling and immune modulation. Founded in 2000, Curis evolved through internal research and multiple strategic collaborations, including long-standing relationships with large pharmaceutical companies, to build a diversified oncology-focused pipeline.
Business Operations
Curis operates as a single-reportable segment focused on oncology drug discovery and development, generating revenue primarily through research collaborations, milestone payments, and licensing arrangements. The company’s internal pipeline includes clinical and preclinical candidates targeting pathways such as IRF5-mediated immune responses and oncogenic signaling in blood cancers, with a particular emphasis on hematologic malignancies.
The company conducts its research and development activities both domestically and internationally. A significant portion of discovery and preclinical research is conducted through its majority-owned subsidiary Aurigene Oncology Limited, based in India, which provides integrated drug discovery capabilities. Curis controls intellectual property related to its drug candidates and leverages external clinical research organizations, academic institutions, and strategic partners to conduct clinical trials and advance development programs.
Strategic Position & Investments
Curis’ strategic direction is focused on advancing its wholly owned and partnered oncology pipeline toward later-stage clinical development while maintaining capital efficiency. Growth initiatives prioritize progressing lead clinical assets, expanding indications for existing candidates, and selectively entering into partnerships that provide non-dilutive funding and development expertise. The company has historically relied on collaborations to offset research costs and to validate its scientific platforms.
A key strategic investment is Curis’ ownership of Aurigene Oncology Limited, which serves as a critical discovery engine and has generated multiple development candidates. Curis continues to invest in emerging oncology technologies, including targeted small molecules and immune-modulating agents, while evaluating external assets that complement its scientific focus. No material acquisitions beyond its existing subsidiary structure have been conclusively disclosed in recent public filings; data inconclusive based on available public sources.
Geographic Footprint
Curis is headquartered in North America, with its corporate offices located in the United States. The company’s operational footprint extends internationally through India, where Aurigene Oncology Limited conducts substantial research and discovery activities. This structure allows Curis to integrate global research capabilities while maintaining centralized strategic and financial oversight.
Through clinical trial activities and collaborations, Curis has an operational presence across multiple regions, including North America, Europe, and parts of Asia, depending on study design and partner involvement. While the company does not maintain commercial infrastructure, its international research and clinical engagements provide global reach within the oncology development ecosystem.
Leadership & Governance
Curis is led by an executive team with experience in biotechnology, oncology drug development, and corporate finance, guiding the company’s strategy toward advancing a focused oncology pipeline and creating long-term shareholder value. The leadership philosophy emphasizes scientific rigor, disciplined capital allocation, and strategic partnerships to manage development risk.
Key executives, as disclosed in recent public filings, include:
- James Dentzer – President and Chief Executive Officer
- James Mason – Chief Financial Officer
- John H. O’Donnell – Chief Medical Officer
Founder-specific attribution and historical board leadership details are not consistently disclosed across public sources; data inconclusive based on available public sources.